MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France, June 24, 2025 – 8:00pm…
Categorie
2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization application of Xervyteg® (MaaT013) in…
June 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed…
June 13, 2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in…
June 2, 2025
• June 18-19, 2025 – Portzamparc Conference Mid & Small Caps 2025, Paris, France
May 15, 2025
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress…
May 14, 2025
MaaT Pharma to Hold Annual General Meeting on June 20, 2025 Lyon, France, May 14, 2025 – 7:30am CET –…
May 14, 2025
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.